Company intelligence / Profile preview
Shanghai IxCell Biotech Co., Ltd.
Shanghai, Shanghai, Chinacmocro.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company's mesenchymal stem cell drug for knee osteoarthritis has completed Phase II clinical trials and is in Phase III, positioning it to become one of China's earliest commercialized stem cell therapies. Their CAR T-cell therapy for lupus has achieved durable medication and symptom-free remission for over 4.5 years[5].
- Therapeutic areas
- PulmonologyRheumatologyImmunologyOncologyNeurologyInfectious Diseases
- Modalities
- Cell therapyStem cell therapyCAR T-cell therapyImmune cell therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Shanghai IxCell Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai IxCell Biotech Co., Ltd..